Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | TLR2 | O60603 | 12/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.42 |
| ▸ | AKT2 | P31751 | 3/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181716 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3TLR2LPAR2AKT1 | |
| SCHEMBL30244929 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3TLR2LPAR2AKT1 | |
| SCHEMBL5979983 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3TLR2LPAR2AKT1 | |
| SCHEMBL25078771 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3TLR2LPAR2AKT1 | |
| SCHEMBL13032606 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3TLR2LPAR2AKT1 | |
| SCHEMBL24208066 | 0.93 | TLR2 (0.43) | LPAR1LPAR3TLR2LPAR2 | |
| SCHEMBL13366871 | 0.90 | CNR1 (0.40) | LPAR1LPAR3TLR2 | |
| SCHEMBL24209900 | 0.89 | ALDH1A1 (0.44) | LPAR1LPAR3TLR2 | |
| SCHEMBL25408144 | 0.89 | ALDH1A1 (0.44) | LPAR1LPAR3TLR2 | |
| SCHEMBL13563940 | 0.88 | LPAR1 (0.32) | LPAR1LPAR3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168222-A1 | LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220168222-A1 | LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168222-A1 | LIPID NANOPARTICLES | PLIN3, LCAT, NPC1L1 | LPAR1 53/4885LPAR3 27/4885TLR2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.